Medical Condition News

RSS

Misperceptions about risk, symptoms and lethality of lung cancer increase mortality rates for lung cancer

A new analysis published this week in the journal Cancer indicates that misperceptions about risk, symptoms and the lethality of lung cancer may play a role in the disproportionately higher incidence and mortality rates for lung cancer among African Americans.

26 Feb 2010

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.

26 Feb 2010

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on HAE

Hereditary angioedema (HAE) can be difficult to accurately diagnose and equally difficult to effectively treat. To overcome the many obstacles to managing the care of patients with HAE, healthcare professionals must be aware of the most up-to-date clinical data regarding HAE diagnosis and treatment.

26 Feb 2010

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.

26 Feb 2010

USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.

26 Feb 2010

New fatigue rating scale predicts increased risk of heart attack in dialysis patients

For dialysis patients, high scores on a new fatigue rating scale predict an increased risk of heart attack or other cardiovascular events, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

25 Feb 2010

BioMedix Vascular Solutions, Howard University Hospital to participate in Community Health Project and Demonstration

BioMedix Vascular Solutions, Inc. announced today that the company has partnered with Howard University Hospital, Department of Surgery to participate in a Community Health Project and Demonstration focused on diagnosing and treating the potentially life-threatening condition called Peripheral Arterial Disease (PAD).

25 Feb 2010

Lawsuit alleges Medtronic illegally marketed stent device for unapproved use

A complaint filed in federal court last week "alleges Medtronic Inc. illegally marketed a relatively obscure medical device called a biliary stent in ways not approved by federal regulators," The (Minneapolis-St. Paul) Star Tribune reports.

25 Feb 2010

FDA sets new PDUFA action date for exenatide once weekly NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) has set a new Prescription Drug User Fee Act (PDUFA) action date of March 12 for its review of the exenatide once weekly new drug application (NDA).

25 Feb 2010

Greater access to rehabilitation after TIA needed to prevent future strokes

Transient Ischemic Attacks (TIA) are often called "mini strokes" for good reasons -- the short-term symptoms can mimic a stroke and up to 10 percent of first-time sufferers often experience full-blown strokes within as little as 90 days. Despite the well-known statistics, no post-TIA regimen exists to help prevent future strokes -- but this might be changing.

25 Feb 2010

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

Interventional radiologists-minimally invasive specialists-will share scientific advances and new discoveries in treating a host of diseases at the Society of Interventional Radiology's 35th Annual Scientific Meeting March 13󈝾 at the Tampa Convention Center, Tampa, Fla. This year's meeting theme is "IR Innovation"-one that celebrates the remarkable inventiveness of interventional radiologists.

25 Feb 2010

IOS Press announces the 20th anniversary of Restorative Neurology and Neuroscience journal

IOS Press is pleased to announce the 20th anniversary of the peer-reviewed journal Restorative Neurology and Neuroscience. Since founded in 1989 by pioneering neuroscientist Donald G. Stein, RNN has focused on the emerging field of brain plasticity, repair and rehabilitation and has published not only numerous original scientific publications, but also review papers in basic research (animal experiments, in vitro studies) and in the clinical sciences.

25 Feb 2010

Study demonstrates Prochymal treamtent is safe for cardiac patients

“Patients receiving Prochymal did better than those receiving only standard-of-care,” said Dr. Hare, lead author of the JACC publication.

25 Feb 2010

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled “PI-3 Kinase Inhibitor Prodrugs.” This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore’s clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.

25 Feb 2010

Family violence survivors: Enhancing resilience a promising therapy

Thousands of men, women and children experience family violence each year, according to the U.S. Department of Justice. Traditionally, therapy for violence survivors has predominantly focused on evaluating their trauma and pain. In contrast, a University of Missouri researcher broadens the therapeutic focus to empower survivors through highlighting their resilience, resourcefulness, and ability to overcome adversity.

25 Feb 2010

Toys"R"Us fundraising campaign to benefit Autism Speaks

Toys"R"Us, U.S. today announced that its fundraising campaign to benefit Autism Speaks will begin Sunday, February 28 and continue through Friday, April 30. Throughout the campaign, monetary donations will be collected at all Toys"R"Us and Babies"R"Us stores and online at Toysrus.com/AutismSpeaks.

25 Feb 2010

Myeloma Canada calls on Quebec government to approve Revlimid as second-line therapy

The Government of Quebec's Ministère de la santé et des services sociaux has approved the addition of Revlimid(R) (lenalidomide) to the Province's Drug Formulary as a third-line therapy for multiple myeloma patients. The cost of the drug will be reimbursed under the Province's medicare system.

25 Feb 2010

Lab research targets 'estrogen-receptor positive' breast cancer cells; identifies key protein

In a laboratory study published in the journal Cancer Research, Scott & White Healthcare anatomic pathologist Arundhati Rao, M.D. is a co-investigator looking at the ways in which estrogen can interfere with how chemotherapy does its job in destroying breast cancer cells.

25 Feb 2010

Saint Louis County Justice Services awards alcohol monitoring contract to EMASS

Eastern Missouri Alternative Sentencing Services (EMASS) has announced that Saint Louis County Justice Services awarded their alcohol monitoring contract for the county's DUI offenders to EMASS and their transdermal alcohol sensors, known as SCRAM (Secure Continuous Remote Alcohol Monitors).

25 Feb 2010

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.

25 Feb 2010

Medical Condition News

Misperceptions about risk, symptoms and lethality of lung cancer increase mortality rates for lung cancer

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on HAE

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

New fatigue rating scale predicts increased risk of heart attack in dialysis patients

BioMedix Vascular Solutions, Howard University Hospital to participate in Community Health Project and Demonstration

Lawsuit alleges Medtronic illegally marketed stent device for unapproved use

FDA sets new PDUFA action date for exenatide once weekly NDA

Greater access to rehabilitation after TIA needed to prevent future strokes

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

IOS Press announces the 20th anniversary of Restorative Neurology and Neuroscience journal

Study demonstrates Prochymal treamtent is safe for cardiac patients

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Family violence survivors: Enhancing resilience a promising therapy

Toys"R"Us fundraising campaign to benefit Autism Speaks

Myeloma Canada calls on Quebec government to approve Revlimid as second-line therapy

Lab research targets 'estrogen-receptor positive' breast cancer cells; identifies key protein

Saint Louis County Justice Services awards alcohol monitoring contract to EMASS

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News